Experimental study demonstrates ROS-triggered carbon monoxide release from organic prodrugs, highlighting a strategy for targeted therapeutic delivery to diseased tissues.
CO prodrugs with triggered release mechanisms are highly desirable for targeted delivery. Herein described are organic CO prodrugs that are activated by ROS and thus can be used to selectively deliver CO to cells with elevated ROS levels. Such CO prodrugs can serve as powerful tools for targeted delivery to disease sites with elevated ROS levels and to explore the therapeutic applications of CO.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: